Membrane Interaction of Chrysophsin-1, a Histidine-Rich Antimicrobial Peptide from Red Sea Bream

Chrysophsin-1 is an amphipathic α-helical antimicrobial peptide produced in the gill cells of red sea bream. The peptide has broad range activity against both Gram-positive and Gram-negative bacteria but is more hemolytic than other antimicrobial peptides such as magainin. Here we explore the membra...

Full description

Saved in:
Bibliographic Details
Published inBiochemistry (Easton) Vol. 46; no. 51; pp. 15175 - 15187
Main Authors Mason, A. James, Bertani, Philippe, Moulay, Gilles, Marquette, Arnaud, Perrone, Barbara, Drake, Alex F, Kichler, Antoine, Bechinger, Burkhard
Format Journal Article
LanguageEnglish
Published United States American Chemical Society 25.12.2007
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Chrysophsin-1 is an amphipathic α-helical antimicrobial peptide produced in the gill cells of red sea bream. The peptide has broad range activity against both Gram-positive and Gram-negative bacteria but is more hemolytic than other antimicrobial peptides such as magainin. Here we explore the membrane interaction of chrysophsin-1 and determine its toxicity, in vitro, for human lung fibroblasts to obtain a mechanism for its antimicrobial activity and to understand the role of the unusual C-terminal RRRH sequence. At intermediate peptide concentrations, solid-state NMR methods reveal that chrysophsin-1 is aligned parallel to the membrane surface and the lipid acyl chains in mixed model membranes are destabilized, thereby being in agreement with models where permeabilization is an effect of transient membrane disruption. The C-terminal RRRH sequence was shown to have a large effect on the insertion of the peptide into membranes with differing lipid compositions and was found to be crucial for pore formation and toxicity of the peptide to fibroblasts. The combination of biophysical data and cell-based assays suggests likely mechanisms involved in both the antibiotic and toxic activity of chrysophsins.
Bibliography:istex:E57CBFBC9A761D35E3FAFCF3C86C99817ECECEF1
This work was supported by Vaincre la Mucoviscidose (TG-0501). B.P is supported by the FP6 Marie Curie Research Training Network BIOCONTROL (MRTN-CT-2006 033439).
ark:/67375/TPS-BQVBSJSL-C
ISSN:0006-2960
1520-4995
DOI:10.1021/bi701344m